Cullen/Frost Bankers, Inc. Krystal Biotech, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.23 Billion
- Q3 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 28 shares of KRYS stock, worth $4,154. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28
Previous 24
16.67%
Holding current value
$4,154
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding KRYS
# of Institutions
309Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$586 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$423 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$389 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$216 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$147 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.81B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...